A large - scale US research released today has demonstrated above 90 percent efficacy for Novavax's COVID-19 vaccine against most COVID-19 variations. The NOVOVAX base vaccine will be manufactured and distributed by Serum Institute of India.
"The jab demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall," said the Maryland headquartered company that conducted the research. The efficacy, immunogenicity and safety of this vaccine was demonstrated in a sample population spread across 119 sites in US and Mexico, comprising of 29,960 persons. Regulatory approval for the vaccine will be processed in the third quarter of 2021, said the company, following which the company will be producing 100 million doses per month initially. The production capacity will increase by 50% to 150 million doses per month towarsd the end of the year.
"Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines." - Stanley C. Erck, Novavax's President and Chief Executive.
Novavax's vaccine, formally known as NVX-CoV2373, does not require storage at ultra-low temperatures, unlike other rival vaccines.
Confirming that the vials will be easier to transport and administer in nations with less developed infrastructure, the company said that it was "stored and stable at 2°- 8°C".